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Abstract
Objectives:
Very little is known about mechanisms of idiosyncratic sensitivity
 to the damaging effects of mercury (Hg); however, there is likely a
 genetic component. The aim of the present study was to search for
 genetic variation in genes thought to be involved in Hg
 metabolism and transport in a group of individuals identified as
 having elevated Hg sensitivity compared to a normal control
 group.
Materials and Methods:
Survivors of pink disease (PD; infantile acrodynia) are a population
 of clinically identifiable individuals who are Hg sensitive. In the
 present study, single nucleotide polymorphisms in genes thought
 to be involved in Hg transport and metabolism were compared
 across two groups: (i) PD survivors (n = 25); and (ii) age- and sex-
matched healthy controls (n = 25).
Results:
Analyses revealed significant differences between groups in
 genotype frequencies for rs662 in the gene encoding paraoxanase 1
 (PON1) and rs1801131 in the gene encoding
 methylenetetrahydrofolate reductase (MTHFR).
Conclusions:
We have identified two genetic polymorphisms associated with
 increased sensitivity to Hg. Genetic variation in MTHFR and
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 PON1 significantly differentiated a group formerly diagnosed with
 PD (a condition of Hg hypersensitivity) with age- and gender-
matched healthy controls.
Keywords: Genetics, mercury sensitivity,
 methylenetetrahydrofolate reductase, pink disease, paraoxanase 1
INTRODUCTION
The potent neurotoxicity of mercury (Hg) has been known for
 centuries, yet it remains in use in a variety of medical, commercial,
 and industrial practices. Of most concern internationally is the fact
 that Hg is widely distributed throughout our food chain, air, water,
 and land at levels that have proven toxic to flora, fauna, and human
 beings.[1] Hg in all its forms (ionic Hg  and Hg /Hg ; vapor
 Hg  and organic alkyl forms MeHg , Me  Hg, EtHg , and Et  Hg)
 has potent neurotoxicity for the brain and particularly for the
 human fetal brain.[2] The central nervous system is a major target
 of Hg, and both high- and low-dose exposure can produce
 significant long-term neurological damage.[3,4] Neurological
 symptoms attributed to Hg intoxication include ataxia, deafness,
 psychosis, loss of speech, erethism, and constriction of the visual
 field.[5] For example, the direct causal link between cerebral palsy
 and Hg exposure to the developing human fetus was first
 established by the Swedish Expert Group in 1971[6] and
 confirmed recently by other researchers.[7,8] For a fetus, Hg brain
 levels can be significantly higher than in maternal blood, and the
 developing fetal brain demonstrates high sensitivity to Hg toxicity.
 Current research has identified that Hg exposure during early
 development (including in utero) is associated with tic disorders,
[9] PD,[10] cerebral palsy, and Hunter–Russell syndrome.[11]
The PD outbreak of the 20  century highlights the potential
 severity of the reaction (including death) that some children may
 have to a low level of Hg exposure,[12] and it is a variable,
 idiosyncratic, and unpredictable individual susceptibility to Hg
 that determines the reaction.[13] In the early 1900s, the increased
 availability of new and untested pharmaceuticals led to the
 exposure of infants to inorganic Hg present as calomel in teething
 powder. Calomel contained Hg levels low enough to not be
 poisonous to the average infant; however, for a small subset of the
 population highly sensitive to Hg, the levels were sufficient to be
 detrimental and produce symptoms, which would eventually be
 classified as a disease entity known as PD or infantile acrodynia.
[12] New cases of PD essentially ceased in the mid-1950s as
 calomel was identified as the causal agent and removed from
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 teething products at that time. Some survivors of PD are still living
 and represent an important cohort of clinically identifiable Hg-
sensitive individuals. Given the ubiquitous nature of low level Hg
 exposure, it remains possible that various adverse health effects are
 manifesting in Hg-sensitive individuals whom we are unable, at
 the present time, to identify on the basis of any clinical or genetic
 testing. Although unproven, various clinical effects have been
 hypothesised to result from low-level Hg exposure including
 autism,[13] tic disorders,[9] and Alzheimer's disease.[14]
 Additionally, the symptoms of an adverse response to Hg have
 been known to mimic various conditions including Parkinson's
 disease,[15] amyotrophic lateral sclerosis,[16] and schizophrenia.
[17] An understanding of the genetic moderators of Hg impact
 would facilitate testing of these hypotheses.
The toxicokinetics and clinical effects of Hg exposure depend
 greatly on the dose, pattern, timing, route of exposure, individual
 excretion rates, and idiosyncratic sensitivity to Hg.[18] There is a
 substantial body of evidence to show that much of the variance in
 Hg sensitivity is determined by genetic factors.[3] The aim of this
 study was to test for association between genetic variation in genes
 involved in Hg transport and metabolism and PD.
MATERIALS AND METHODS
Ethical approval for this study was granted by the Deakin
 University Human Research Ethics Committee.
Participants
Survivors of PD: Potential participants were drawn from the
 database of PD survivors held by the Australian Pink Disease
 Support Group (http://www.pinkdisease.org/). A recruitment
 notice was placed on the group's website as well as emailed to all
 members who had supplied an email address. The notice stipulated
 that participants must have received a formal diagnosis of PD as a
 child and be residing within 200km of Sydney or Melbourne,
 Australia. Following receipt of informed consent from 25
 volunteers, a suitable time was arranged for a qualified nurse to
 visit their residence. Participants had 2 × 10 ml of blood drawn.
 The blood samples were then transported to Genetic Repositories
 Australia whereupon cell lines were created. Extracted
 deoxyribonucleic acid (DNA) was then supplied to the research
 team. The PD survivor sample ranged in age from 60 to 75 years
 (22 females and three males) and had a mean age of 65.7 years (SD
 = 3.9).
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Healthy controls: Age- and sex-matched healthy control DNA (n =
 25) was procured from the Baker IDI Heart and Diabetes Institute
 Biobank. The healthy control sample was drawn from 22 females
 and 3 males ranging in age from 59 to 75 years with a mean age of
 65.9 years (SD = 5.3).
For all samples, DNA concentration was adjusted to 50 ng/μl in TE
 buffer (10mM Tris-HCl, 1mM ethylenediaminetetraacetic acid
 (EDTA)•Na  (pH 8.0)) and stored at −20°C.
Genotyping
Genetic polymorphisms associated with Hg metabolism and
 toxicity were identified by literature search. Details of the
 candidate genes associated with increased sensitivity to Hg are
 shown in Table 1. A total of 16 polymorphisms were genotyped in
 this study, 13 of them by polymerase chain reaction (PCR)
 restriction fragment length polymorphism. Presence/absence of
 GSTM1 and GSTT1 was assessed by multiplex PCR with albumin
 as positive control. The 15 bp insertion/deletion polymorphism
 (rs11267756) in SLC7A5 was assessed by PCR and agarose gel
 electrophoresis.
Table 1
Candidate genes associated with
 increased sensitivity to Hg
Standard PCRs were conducted using 100 ng of DNA, 1 U Taq
 polymerase (Invitrogen, Melbourne, Australia), 200 μM each
 dNTP, 0.5 μM forward and reverse primer, 20 mM Tris-HCl pH
 8.4, 50 mM KCl, and 2 mM MgCl  in a total volume of 20 μl. The
 multiplex PCR for GSTM1, GSTT1, and albumin was conducted
 using 100 ng of DNA, 2 U Taq polymerase (Invitrogen), 400 μM
 each dNTP, 0.3 μM GSTM1 primers, 0.2 μM GSTT1 primers,
 0.15 μM albumin primers, 20 mM Tris-HCl pH 8.4, 50 mM KCl,
 and 3 mM MgCl2 in a total volume of 20 μl.
Following PCR, 10 μl of each PCR product was purified using
 QIAquick PCR Purification kits (Qiagen, Melbourne, Australia)
 and eluted in 20 μl of nuclease-free water.
Restriction digestion of purified PCR products was conducted
 using 10 μl of purified DNA, 5-20 U restriction enzyme, and 1x
 corresponding restriction enzyme buffer, made up to a total
 volume of 20 μl with nuclease-free water.
2
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Following restriction digestion, the samples were separated using
 agarose gel electrophoresis (1-5%, depending on product size),
 labeled with SybrSafe (Invitrogen) and visualized under ultraviolet
 (UV) light. Genotype calling was conducted blindly by two
 independent reviewers.
RESULTS
Hardy–Weinberg equilibrium and genotype frequencies for PD
 survivors and control group participants were compared using
 Fisher's exact test. Analyses were performed using IBM Statistical
 Package for Social Sciences (SPSS) 21. Genotype frequencies
 were considered to be different between groups at P < 0.05. The
 summary results for all polymorphisms are shown in Table 2.
Table 2
Genotype data for 16 candidate gene
 polymorphisms in pink disease
 survivors and matched control
 subjects
The only significant difference in genotype frequencies between
 PD survivors and controls were found for
 methylenetetrahydrofolate reductase (NAD (P) H) (MTHFR) at
 rs1801131 (χ  = 6.13, P = 0.039) and for paraoxonase 1 (PON1) at
 rs662 (χ  = 7.04, P = 0.030). Representative digests for the various
 genotypes are shown in Figure 1.
Figure 1
Representative genotyping results for
 (a) MTHFR rs1801131 and (b)
 PON1 rs662
Hardy–Weinberg equilibrium was present for all polymorphisms
 examined, except for rs1801131 in the MTHFR gene (χ  = 5.68, P
 < 0.05) and rs1050450 in GPX1 (χ  = 6.17, P < 0.05).
DISCUSSION
The old toxicology adage attributed to Paracelsus, “the dose makes
 the poison” is an incomplete and insufficient model of
2
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 toxicokinetics, with modern perspectives emphasizing the large
 individual variance in response to any given dose of a toxicant.[18]
 Therefore, in order to comprehensively understand the etiology of
 clinical syndromes arising from Hg exposure, it is critical to
 understand individual sensitivity. Here we report the first study of
 Hg sensitivity based on genetic variance amongst survivors of PD,
 a condition which is the result of an idiosyncratic sensitivity to Hg.
[12]
In this study, we found polymorphisms in two genes that
 differentiated PD survivors from age- and gender-matched healthy
 control subjects. This suggests a possible role in Hg sensitivity.
 The associated single nucleotide polymorphisms were rs662,
 which results in a glutamine to arginine substitution at position
 192 of PON1, and rs1801131, which causes a glutamic acid to
 alanine substitution at amino acid 429 of MTHFR. Neither of these
 polymorphisms have previously been associated with sensitivity to
 Hg or other heavy metals, although studies have shown that heavy
 metals, including Hg, can affect PON1 activity levels.[19]
PON1 plays an important role in the hydrolysis and detoxification
 of several organophosphate insecticides, including diazinon and
 parathion, the nerve gases sarin and soman, and aromatic esters
 and lactones. Although no direct role for PON1 in the
 detoxification of Hg has been demonstrated, it is feasible that it
 could play a role and that this genetic variation at rs662, which is
 known to affect enzymatic activity, could affect the ability of the
 enzyme to protect against the toxic effects of Hg. Previous studies
 have shown association between genetic polymorphism in PON1
 (including rs662) and a range of clinical disorders including
 coronary artery disease,[20] microvascular complications of
 diabetes,[21] and macular degeneration.[22] In most cases, these
 associations are thought to be driven by altered metabolism and
 levels of oxidized lipids in subjects with genetic variation in
 PON1.
MTHFR catalyzes the conversion of 5,10-methyle
 netetrahydrofolate to 5-methyltetrahydrofolate, a cosubstrate for
 homocysteine remethylation to methionine. This enzyme therefore
 plays a crucial role in amino acid and folate metabolism. MTHFR
 deficiency results in homocysteinemia and altered folate
 metabolism, and it has been studied extensively in the context of a
 range of diseases. Genetic variation in MTHFR has been
 reproducibly associated with neural tube defects,[23] vascular
 disease,[24] cleft lip/palate,[25] depression,[26] and schizophrenia.
[27,28] For many of these associations, there appears to be
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 interaction between genetic variation in MTHFR and plasma levels
 of either homocysteine or folate metabolites (or both), suggesting
 that MTHFR may act as a modifier of disease risk.
The rs1801131 polymorphism in MTHFR was not in Hardy–
Weinberg equilibrium in our participants. This is consistent with
 published studies showing deviations from Hardy–Weinberg
 expectations that suggest there may be selective pressures for
 sequence variation in this gene.[29] Furthermore, a previous study
 provided data to suggest that mutations in MTHFR may have
 occurred on a founder haplotype with a selective advantage.[30]
A limitation of the study was the modest sample size of 50. This
 figure was a function of both funding limitations and challenges in
 communicating with and recruiting PD survivors. The PD survivor
 population is diminishing through age-related mortality, with the
 youngest survivors born in the 1950s. It is a very small, elderly,
 and unique population. As a result of the sample size, statistical
 power was, of course, impacted. Although the statistical analyses
 conducted were conservative and therefore accounted for the low
 power, it remains important to note the number of comparisons
 conducted (16) and interpret the results cautiously in light of the
 possibility of type I error.
Despite these challenges, the PD survivor population remains, to
 our knowledge, the only identifiable clinical population of
 individuals that have a demonstrated history of Hg sensitivity.
 They remain a vitally important population to researchers aiming
 to further our understanding of Hg sensitivity. The issue is
 particularly salient as low level Hg exposure is ubiquitous and the
 potent neurotoxicity of Hg is well established as being especially
 devastating to the central and peripheral nervous systems of infants
 and unborn babies.[3]
Beyond this emerging understanding of how Hg may affect
 individuals at doses known to produce clinical effects, there is less
 certainty as to predicting who is most at risk, and why, as a result
 of our lack of understanding of individual difference variables
 related to Hg sensitivity. This study contributes to our knowledge
 in this area by identifying two genetic variants that significantly
 differentiate healthy controls from a clinical population of Hg-
sensitive individuals. Of course, there are likely many more genetic
 variables contributing to Hg sensitivity that await identification.
CONCLUSIONS
In this study, we have identified two genetic polymorphisms
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 associated with increased sensitivity to Hg. Our results showed
 that genetic variation in MTHFR and PON1 significantly
 differentiated a group formerly diagnosed with PD (a condition of
 Hg hypersensitivity) with age- and gender-matched healthy
 controls. Given the range of diseases in which Hg has been
 implicated, these findings will facilitate further investigation into
 the source and mechanisms of Hg sensitivity with far-ranging
 clinical implications.
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